Xilio Therapeutics (XLO) EPS (Basic) Growth (1y) (2021 - 2026)
Xilio Therapeutics (XLO) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | 29.25% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.03 Bn | 467.24 Bn | 1.35 Bn | 17,151.81% |
| 5 | Vertex Pharmaceuticals | 122.09 Bn | 114.84 Bn | 2.59 Bn | 61.34% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | -7.74% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.99 Bn | 50.80 Bn | 1.41 Bn | 88.81% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 1,201.33% |
| 10 | Xilio Therapeutics | 142.71 Mn | -7.59 Mn | - | 66.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.84% |
| Dec 31, 2025 | 61.01% |
| Sep 30, 2025 | 94.08% |
| Jun 30, 2025 | 42.02% |
| Mar 31, 2025 | 70.80% |
| Dec 31, 2024 | 62.80% |
| Sep 30, 2024 | 62.97% |
| Jun 30, 2024 | 64.96% |
| Mar 31, 2024 | 26.29% |
| Dec 31, 2023 | 21.62% |
| Sep 30, 2023 | 15.17% |
| Jun 30, 2023 | 18.91% |
| Mar 31, 2023 | -10.52% |
| Dec 31, 2022 | 74.57% |
| Sep 30, 2022 | 98.21% |
| Jun 30, 2022 | 97.11% |
| Mar 31, 2022 | 96.68% |
| Dec 31, 2021 | 91.47% |
| Sep 30, 2021 | -71.87% |